Page 13 - Mabthera Rituxan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mabthera rituxan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mabthera Rituxan Today - Breaking & Trending Today

F. Hoffmann-La Roche Ltd: Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma

Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June ....

United States , Nathalie Meetz , Levi Garraway , Jon Kaspar Bayard , Karl Mahler , Mabthera Rituxan , Gazyva Gazyvaro , Sabine Borngr , Gerard Tobin , Bruno Eschli , Venclexta Venclyxto , Birgit Masjost , Loren Kalm , Patrick Barth , Karsten Kleine , International Prognostic Index , Drug Administration , Head Of Global Product Development , Drug Administration Breakthrough Therapy Designation , Roche Group , Pharmaceuticals Industry , Roche Group Media Relations , Chief Medical Officer , Global Product , Nonproprietary Naming , Biological Products Guidance ,

F. Hoffmann-La Roche Ltd: European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy

F. Hoffmann-La Roche Ltd: European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
leukaemia
azacitidine
significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall survival rate of less than 10%
1
Venclyxto
-based combinations to provide clinically meaningful benefits in difficult to treat blood cancers
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. ....

United States , Nathalie Meetz , Jon Kaspar Bayard , Levi Garraway , Karl Mahler , Mabthera Rituxan , Sabine Borngr , Gerard Tobin , Bruno Eschli , Venclexta Venclyxto , Birgit Masjost , Loren Kalm , Lisa Tuomi , Patrick Barth , Karsten Kleine , National Cancer Institute , Leukemia Lymphoma Society , European Commission , Drug Administration , Cancer Treatment Centers Of America , Head Of Global Product Development , Roche Group , Roche Group Media Relations , Chief Medical Officer , Global Product , Breakthrough Therapy Designations ,

Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates

Pharma Stock Roundup: JNJ s Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates
Zacks.com
2 hrs ago
J&J JNJ announced strong first-quarter results, beating estimates for both earnings and sales.
Roche’s RHHBY COVID-19 diagnostics tests sales boosted the top line, offsetting declines in its core drug business. The FDA granted approval to
Glaxo’s GSK endometrial cancer therapy, Jemperli (dostarlimab).
Recap of the Week’s Most Important Stories
J&J Earnings & Sales Beat: J&J beat first-quarter estimates for earnings as well as sales. Its Pharmaceuticals unit continued to perform above market levels while the recovery in the Medical Devices unit continued. However, unfavorable comparisons to the year-ago quarter due to COVID-19 pantry loading and demand surges experienced in 2020 hurt sales of the Consumer Health segment in the first quarter of 2021 ....

United States , Sanofi Sarclisa , Mabthera Rituxan , Amgen Kyprolis , Pharmacovigilance Risk Assessment Committee , Us Centers For Disease , Its Pharmaceuticals , Large Cap Pharmaceuticals Industry , European Commission , Drug Development , European Union , European Medicines Agency , Consumer Health , Most Important , Sales Beat , Medical Devices , Disease Control , Endometrial Cancer Drug , Seeks Revocation , Emergency Use Authorization , Second Indication , More Doses , Cap Pharmaceuticals Industry , Zacks Top , ஒன்றுபட்டது மாநிலங்களில் , மருந்தியல் ஆபத்து மதிப்பீடு குழு ,

Roche sees continued strong impact of biosimilars

Roche witnessed a slight decrease in Q1 2021 pharmaceutical sales – a drop of 9% compared to the first three months of 2020 - as it faced continued biosimilars competition; the COVID-19 pandemic also played a role.
The company reported yesterday [April 21] that sales in its pharmaceutical division dipped 9% to CHF 10.6bn (US$11.54bn).
The pandemic also served to undermine the pharmaceutical division’s sales, especially for medicines where regular visits to hospitals or health practices are needed, such as infusions. Partly compensating that negativity, however, were the additional sales of medicines used to treat COVID-19, said Roche.
New medicines, those launched since 2012, grew by 20% and generated sales of CHF 5.2bn in the quarter, said the pharma giant. ....

Mabthera Rituxan , Actemra Roactemra ,

Roche Backs 2021 Views After 1Q Sales Fall Slightly

By Olivia Bugault
Roche Holding AG said Wednesday that sales slightly decreased in its first quarter, while it confirmed its outlook for the year.
The Swiss pharmaceutical major posted sales of 14.93 billion Swiss francs ($16.30 billion), down from CHF15.14 billion a year earlier. At constant exchange rate, sales increased 3%, it said.
An analysts consensus provided by FactSet had sales at CHF15.01 billion.
Sales at its pharmaceuticals division its largest business fell to CHF10.6 billion from CHF12.26 billion, while it rose 55% at constant exchange rate at its diagnostic division, it said.
The decline in sales at its pharmaceuticals business is mainly because of the coronavirus pandemic and the competition of biosimilars, Roche said. The impact of biosimilars on sales of the established cancer medicines MabThera/Rituxan, Avastin and Herceptin remained significant (combined sales reduction of CHF1.6 billion), especially in the U.S., it said ....

Mabthera Rituxan , Olivia Bugault , Roche Holding , Dow Jones , Roche Holding Ag Stock Exchange , Press Release , Ajor Rog Ch0012032048 , ரோச் வைத்திருத்தல் , டோ ஜோன்ஸ் ,